Table 1.

Proportions of composite responders among patients completing and discontinuing from the studies over weeks 1–26: pooled Phase 3 studies

	Placebo (n = 809)	Eluxadoline 75 mg (n = 808)	Eluxadoline 100 mg (n = 806)
Patients completing	Placebo (n = 563)	Eluxadoline 75 mg (n = 539)	Eluxadoline 100 mg (n = 556)
Responders, n (%)	150 (26.6)	208 (38.6)	235 (42.3)
Patients discontinuing	Placebo (n = 246)	Eluxadoline 75 mg (n = 269)	Eluxadoline 100 mg (n = 250)
Responders, n (%)	8 (3.3)	8 (3.0)	15 (6.0)

A completer is defined as a patient who either had the last day of diary data or last treatment date on or later than day 182, or whose case record form was checked ‘Yes’ on the completion page. A discontinuer is defined as a patient whose case record form was checked ‘No’ on the completion page. Composite response is based on daily improvement of ≥30% in worst abdominal pain score compared with average baseline pain and, on the same day, a Bristol Stool Form Scale score of <5, on ≥50% of treatment days.